COBALT Legal’s Post

Dimension, a NYC-based venture capital firm that invests in founders combining technology and life sciences, reportedly raised $500m for its second fund. Dimension partners with entrepreneurs, academics, and engineers to turn their ideas into businesses that span the tech and bio ecosystem. The portfolio includes Chai Discovery, Monte Rosa Therapeutics, Kimia Therapeutics, Automata, NewLimit, Enveda Biosciences, Kaleidoscope Bio, and Lamin. https://lnkd.in/gQ3Dbgc4

We are proud to share that our innovative laryngeal mask project, developed for innoMask, has entered its next development phase. The significance of this work is highlighted by recent investments from leading Hungarian venture capital firms, including the regional Széchenyi Funds Ltd. and Óbuda Uni Venture Capital, Hungary's first university-led investor. These investments demonstrate confidence in our capabilities and reinforce our commitment to delivering this project at the highest standard as soon as possible. #MedRes #Innovation #MedTech #Healthcare

We said there would be more... > We’re thrilled to announce $𝟭𝟯𝟬𝗠 𝗶𝗻 𝗦𝗲𝗿𝗶𝗲𝘀 𝗖 𝗳𝘂𝗻𝗱𝗶𝗻𝗴 led by Kinnevik and FPV Ventures , with participation from Baillie Gifford , Premji Invest , Lux Capital , True Ventures, Dimension and many more new and existing partners. With this new capital, we plan to advance multiple drug candidates through Phase 1/2 clinical trials. In just 𝟰 𝘀𝗵𝗼𝗿𝘁 𝘆𝗲𝗮𝗿𝘀 𝘀𝗶𝗻𝗰𝗲 𝗼𝘂𝗿 𝘀𝗲𝗲𝗱 𝗿𝗼𝘂𝗻𝗱, we’ve gone from a concept to a 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹-𝘀𝘁𝗮𝗴𝗲 𝗰𝗼𝗺𝗽𝗮𝗻𝘆 with a deep pipeline of 𝟭𝟬 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗰𝗮𝗻𝗱𝗶𝗱𝗮𝘁𝗲𝘀. 🚀 Thanks to the hard work of our team and the power of our platform, we’re delivering drug candidates 𝟰𝘅 𝗳𝗮𝘀𝘁𝗲𝗿 𝘁𝗵𝗮𝗻 𝗶𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗮𝘃𝗲𝗿𝗮𝗴𝗲—a testament to our thesis, technology, and team. This marks a significant step forward in our journey to transform the future of drug discovery. A heartfelt thank you to our investors, partners, and, most importantly, our talented team for making this possible. Here’s to the next chapter of growth, discovery, and development! 💊💡 Learn more here: https://lnkd.in/g6M4vXST Read our feature in Bloomberg here: https://lnkd.in/gwZM92F2 #SeriesCFunding #BiotechInnovation #ClinicalStageBiotech #fundrasing #Teamwork

So happy to share this update!!

Atlas Venture, which counts 56 portfolio biotechs, is looking at keeping its 14th fund the same size as its 13th: $450 million. The firm had progressively increased the size of its last few funds but is looking at a "disciplined" new fund, according to an annual review presentation posted on Monday, Nov. 18. Atlas raised $280 million for its 10th fund in 2015, $350 million in 2017, $400 million in 2020 and then $450 million for its 13th batch in 2022. Atlas has been quite active in 2024. It has disclosed investments in about a dozen private biotechs, according to the presentation. One of those, obesity biotech Kailera, secured one of the industry’s largest private funding rounds of this year. About 10 more have been made in stealth mode, according to the presentation. #biotech #biotechventurecapital #lifesciencesvc #biotechvc #atlasventure

Insights from SACHS 2024 - Biovance Capital’s Connection to Switzerland Biotech Ecosystem. As Principal at Biovance Capital, Portugal's new biotech VC fund, I had the privilege of attending SACHS 2024 in Basel during the last 3 days. This event was a powerhouse of knowledge, highlighting the latest trends in biopharma dealmaking and biotech markets. The real value, however, lay in the chance to engage with Switzerland's dynamic biotech ecosystem. Staying connected to such a vibrant network and disruptive startups enriches Biovance's dealflow and strengthens our relationships with specialised and top-tier venture capital investors. The experience reaffirmed the importance of collaboration, and I’m excited to bring these insights back to Biovance as we continue to support groundbreaking biotech advancements in Portugal and in Europe. #BiotechVC #SACHS2024 #BiovanceCapital #BiotechInnovation #Swissbiotech

I get asked all the time if I know of any good resources to get connected with the life science investor community. I'm not raising for dovetail biopartners (and don't ever plan too 🥾) but I still see the benefits of building relationships with people in that world. And I like to help out. So go fill out the application in this link if you're looking for a more traditional way to raise cash. And check out my last post about a webinar for non-traditional ways to raise.

Loved our chat after this interview. What really drives us forward? For Alex Leech, it’s about improving people’s health on a large scale and making a difference through innovation. It’s his passion for helping others that motivates him to get up every morning and work hard to bring life-changing ideas to market. When Alex asked me what drives me, it made me reflect. While I admire the big-picture thinking, my approach is more focused on the small, meaningful steps we can take in the moment. I want to make an impact in the here and now. Whether it’s offering a smile that lifts someone’s mood, holding the door open for someone, or just bringing positive energy into someone’s day. In the end, both of us share the same goal: to help people. Whether it’s through large-scale innovation or small acts of kindness, it’s the desire to make a difference that keeps us going.

Recent developments in health are pretty exciting, focusing on bridging the gap between treatment and prevention and leveraging AI for automation and early disease detection. For instance, Octopus Investments Ventures highlighted the consumerisation of healthcare and AI-led automation as critical trends. Additionally, Israeli venture capital firm Pitango raised $175 million for a healthcare fund, investing in startups like Nevia Bio for women's health and QuantHealth for AI-led clinical trial simulations. #Healthtech

Don’t miss our interview with Christer Fåhraeus at the BioStock Life Science Summit!   Get an exclusive look at the vision behind Fåhraeus Startup and Growth Fund, a venture capital fund co-founded by Christer Fåhraeus and Emanuel Eriksson. In the interview, Christer shares how the fund focuses on investing early in life science and tech companies with high potential, supporting their growth journey.   Watch the interview now to learn more about their approach!